ALK-201

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameALK-201
Drug Alias NameALK201ALK-201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionFibroblast Growth Factor Receptor 2b modulators
TargetsFibroblast Growth Factor Receptor 2b
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Allink Biotherapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Allink Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A